# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
TriSalus Life Sciences, Inc. (NASDAQ:TLSI), an oncology company integrating its novel Pressure Enabled Drug Delivery™ (PEDD™) t...
Canaccord Genuity analyst William Plovanic initiates coverage on TriSalus Life Sciences (NASDAQ:TLSI) with a Buy rating and ...
TriSalus Life Sciences (NASDAQ:TLSI) reported quarterly losses of $(0.60) per share which beat the analyst consensus estimate o...
JonesTrading analyst Justin Walsh initiates coverage on TriSalus Life Sciences (NASDAQ:TLSI) with a Buy rating and announces...
$25 million funded at close; up to $25 million of additional capital available at the Company's option, based on the achiev...